AKRO Research and Charts

AKRO - Akero Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-02-07 (Delayed quote data 2025-01-03)

Last 28.24	Change ⇑ +0.16 (+0.57%)	Volume 725,346
	Open 28.09	High 28.73	Low 27.86

8EMA (Daily) 28.35	40EMA (Daily) 29.59	50EMA (Daily) 29.60	STO (Daily) 17.257	MACD Hist (Daily) -0.184
8EMA (Weekly) 29.470	40EMA (Weekly) 28.00	50EMA (Weekly) 28.00	STO (Weekly) 32.345	MACD Hist (Weekly) -0.767


Company Profile
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.